Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Obinutuzumab for Relapsing PR3-ANCA Granulomatosis With Polyangiitis
NCT06940661Phase 2Recruiting
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Dec 2025
- Primary completion
- Dec 2027
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of obinutuzumab in granulomatosis with polyangiitis (GPA), sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoint: Clinical and Serological Remission at 24 weeks. Started Dec 2025; status: recruiting.
02
Drugs
obinutuzumab
03
Conditions
granulomatosis with polyangiitis (GPA)
Beyond the preview
Go deeper on NCT06940661.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06940661.